Obesity's Impact on Heart Health

Palo Alto (17 mi)

Overseen byJeanne M Link, PhD

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase < 1

Waitlist Available

Sponsor: Oregon Health and Science University

No Placebo Group

Trial Summary

What is the purpose of this trial?A multidisciplinary investigation examining the circadian mechanisms regulating cardiovascular (CV) risk in obesity. Specifically, in a valid circadian protocol, the investigators aim to study resting cardiovascular risk markers and the reactivity of circadian rhythms in these risk markers to standardized stressors in obesity. Furthermore, using an ingenious approach, the investigators propose to explore impairment in pre/post synaptic function in the cardiac left ventricle.

Eligibility Criteria

This trial is for adults aged 25-65 who are not very active and have a body mass index (BMI) between 18.5 to 40, meaning they range from normal weight to obese. It's not open to smokers, those with sleep issues like insomnia or severe sleep apnea, anyone on prescription meds or using drugs of abuse, or people with certain medical conditions including diabetes and high blood pressure.

Inclusion Criteria

I am between 25 and 65 years old.

Exclusion Criteria

I have a long-term health condition like diabetes or high blood pressure.

I have been diagnosed with moderate to severe sleep apnea.

Treatment Details

The study is looking at how the body's daily rhythms affect heart health in overweight individuals by measuring cardiovascular risk markers at rest and in response to stress. Participants will undergo PET imaging using specific tracers like 11C-CGP12177 and mHED as well as O15-water to assess heart function.

2Treatment groups

Experimental Treatment

Group I: OverweightExperimental Treatment5 Interventions

Healthy obese \[30≤BMI\<40 and waist circumference (WC) ≥94/80 (men and women respectively)\] will participate in a 5-day circadian study protocol with PET imaging using radiopharmaceuticals (11C-meta-hydroxyephedrine, 11C-CGP12177, and O15-water).

Group II: Normal WeightExperimental Treatment5 Interventions

Healthy lean controls \[18.5\<BMI\<25 kg/m2 and WC \<94/80 (men and women respectively)\] will participate in a 5-day circadian study protocol with PET imaging using radiopharmaceuticals (11C-meta-hydroxyephedrine, 11C-CGP12177, and O15-water).